|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM322414490 |
| 003 |
DE-627 |
| 005 |
20231225182006.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202005155
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1074.xml
|
| 035 |
|
|
|a (DE-627)NLM322414490
|
| 035 |
|
|
|a (NLM)33684242
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Liang, Pingping
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Monotherapy and Combination Therapy Using Anti-Angiogenic Nanoagents to Fight Cancer
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 02.11.2021
|
| 500 |
|
|
|a Date Revised 02.11.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2021 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Anti-angiogenic therapy, targeting vascular endothelial cells (ECs) to prevent tumor growth, has been attracting increasing attention in recent years, beginning with bevacizumab (Avastin) through its Phase II/III clinical trials on solid tumors. However, these trials showed only modest clinical efficiency; moreover, anti-angiogenic therapy may induce acquired resistance to the drugs employed. Combining advanced drug delivery techniques (e.g., nanotechnology) or other therapeutic strategies (e.g., chemotherapy, radiotherapy, phototherapy, and immunotherapy) with anti-angiogenic therapy results in significantly synergistic effects and has opened a new horizon in fighting cancer. Herein, clinical difficulties in using traditional anti-angiogenic therapy are discussed. Then, several promising applications of anti-angiogenic nanoagents in monotherapies and combination therapies are highlighted. Finally, the challenges and perspectives of anti-angiogenic cancer therapy are summarized. A useful introduction to anti-angiogenic strategies, which may significantly improve therapeutic outcomes, is thus provided
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a anti-angiogenic therapy
|
| 650 |
|
4 |
|a combination therapy
|
| 650 |
|
4 |
|a monotherapy
|
| 650 |
|
4 |
|a nanoparticles
|
| 650 |
|
7 |
|a Angiogenesis Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Drug Carriers
|2 NLM
|
| 650 |
|
7 |
|a Lipids
|2 NLM
|
| 650 |
|
7 |
|a Metals
|2 NLM
|
| 650 |
|
7 |
|a Polymers
|2 NLM
|
| 700 |
1 |
|
|a Ballou, Byron
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lv, Xinyi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Si, Weili
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bruchez, Marcel P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Wei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dong, Xiaochen
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 33(2021), 15 vom: 01. Apr., Seite e2005155
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:33
|g year:2021
|g number:15
|g day:01
|g month:04
|g pages:e2005155
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202005155
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 33
|j 2021
|e 15
|b 01
|c 04
|h e2005155
|